PRECISE‐AD, A Phase 1b, Double‐Blind, Placebo‐Controlled, Multiple Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PMN310 in Patients with Early Alzheimer's Disease
PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against AβO on biomarkers associated with AD pathology and clinical outcomes.
Authors
- Ebrima Gibbs (ORCID: https://orcid.org/0000-0002-6383-9239)
- Johanne Kaplan
- Larry D. Altstiel
- Neil R Cashman
- Misty Lamendola
- Gavin Malefant
- Wendy Luca
Institutions
- University of British Columbia (CA)
- Amorfix (Canada) (CA)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70859_103159
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00